Monthly Archives: November 2011

API2-MALT1 fusion protein appears to trigger cancer

What happens when two proteins join together? In this case, they become like a power couple, where the whole is greater than the sum of the parts. API2 and MALT1 are two proteins that become fused together in a subset … Continue reading

Posted in Uncategorized | Leave a comment

Annual mammogram screening at younger age reduces breast cancer deaths

A new study questions the controversial U.S. Preventative Service Task Force recommendations for breast cancer screening, with data that shows starting at a younger age and screening more frequently will result in more lives saved. As part of their recommendation, … Continue reading

Posted in Uncategorized | Leave a comment

HIV causes specific subset of CD4+ T-cells to age rapidly: Study

In the early years of the AIDS epidemic, being infected with the virus that causes the disease was considered a virtual death sentence. But with the development of antiretroviral therapy, many with HIV are now living much longer. In fact, … Continue reading

Posted in Uncategorized | Leave a comment

Magnetic nanoparticles for ovarian cancer treatment

A paper published in the January issue of the journal Nanomedicine could provide the foundation for a new ovarian cancer treatment option – one that would use an outside-the-body filtration device to remove a large portion of the free-floating cancer … Continue reading

Posted in Uncategorized | Leave a comment

Interim results from ganetespib Phase 2 trial in NSCLC to be presented at 11th IASLC annual meeting

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that Dr. Jonathan Goldman, M.D., Premiere Oncology will present interim results from a Phase 2 trial of ganetespib … Continue reading

Posted in Uncategorized | Leave a comment

Positive results from RXi's sd-rxRNA technology for development of novel therapeutics

RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutics, announced today that, as part of its collaboration with miRagen Therapeutics, positive data were generated demonstrating that RXi’s sd-rxRNA technology can be used, in vitro, to specifically enhance the activity of … Continue reading

Posted in Uncategorized | Leave a comment

Gene signature can accurately predict breast cancer outcomes

Researchers from McGill University’s Rosalind and Morris Goodman Cancer Research Centre, the Research Institute of the McGill University Health Centre, the Dana-Farber Cancer Institute and Harvard Medical School have discovered a gene signature that can accurately predict which breast cancer … Continue reading

Posted in Uncategorized | Leave a comment